Navigation Links
Lazarus Effect Closes $5 Million Financing
Date:7/31/2014

CAMPBELL, Calif., July 31, 2014 /PRNewswire/ -- Lazarus Effect, a medical device company focused on the development of novel interventional devices to facilitate removal of blood clots, announced the closing of a $5 million financing. Proceeds from the financing will support EU commercialization of several approved Lazarus Effect devices, as well as regulatory filings for the Lazarus ReCover™ and Lazarus Cover™ in the United States.

"This financing reflects investor confidence in the value of our novel, platform technology as well as our recent IP and regulatory progress," said Martin Dieck, chairman and CEO, Lazarus Effect. "Our expert team has a track record of bringing high-value neurointerventional products to market, and we are grateful to our investors for helping us replicate this success with Lazarus Effect."

Lazarus Effect is developing a complete portfolio of vascular-device products to facilitate removal of blood clots based on a patented, wire-frame technology platform. The company currently has five issued US patents and numerous pending US and worldwide patent applications. The Lazarus Funnel™ Guide Catheter and Lazarus ReCover devices have CE Mark for use in Europe, and the Funnel is cleared for use in the United States. The Lazarus Cover is pending CE Mark. Neither the ReCover nor the Cover are approved for sale in the United States.

New findings from a study evaluating the ability of the Lazarus Cover to prevent emboli during clot retrieval versus the current standard were presented today at the Society of Neurointerventional Surgery (SNIS) 11th Annual Meeting in Colorado Springs, CO.  Alexander Khalessi, MD, MS, director of Endovascular Neurosurgery and surgical director of Neurocritical Care at the University of California, San Diego, shared data from simulated thrombectomy procedures performed in an anatomical model which demonstrated that the Lazarus Cover can protect captured embolic material during withdrawal, potentially reducing the risk of embolization.

Forward-looking Statements

Statements contained in this press release about Lazarus Effect, Inc. that are not purely historical, and all other statements that are not purely historical, may be deemed to be forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Without limiting the foregoing, the words "believes," "anticipates" and "expects" and similar expressions, are intended to identify forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by these forward-looking statements. Important factors that may cause or contribute to such differences include changes in market or financial conditions, and other changes beyond the control of the Company. The Company specifically disclaims any obligation to update these forward-looking statements.


'/>"/>
SOURCE Lazarus Effect
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Lazarus Effect Receives Notice of Allowance for New US Patent Covering Core Protection Technology
2. Over Half of Audited Multiple Sclerosis Patients Currently Treated with Biogen Idecs Tecfidera Have Experienced Minor Side Effects Although Impact on Use Appears Muted
3. New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice
4. Clinical Trial Demonstrates That EarlySense May Be An Effective Indicator for Respiratory Pattern Recognition
5. New England Journal of Medicine Study Finds Upper-Airway Electronic Stimulation Effective for Obstructive Sleep Apnea
6. ObamaCare: Health Care Reform and its Effect on Sleep Apnea
7. Improving the Quality and Effectiveness of Marketing Services Groups in an Environment Characterized by Globalization and Shrinking Resources
8. New England Journal of Medicine releases study showing GSKs FluLaval Quadrivalent vaccine effective in preventing seasonal flu in children
9. Ibrutinib Data Published in The Lancet Oncology Suggest a Positive Effect in Previously Untreated Chronic Lymphocytic Leukemia Patients Over Age 65
10. Highland Instruments, Inc., Announces Presentation of "Effects of Electrosonic Stimulation on the Perception of Chronic Pain Due to Osteoarthritis of the Knee."
11. Frost & Sullivan Applauds Definiens Strong Technology Portfolio for the Effective Data Analysis of Histology Images
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2017)... , Sept. 5, 2017  Just 18 months ... Insight is pleased to announce the appointment of three ... Tammy Wynne , Dominic Jones-Phillips and ... industry. Tammy ... team of market access writers. She has over ten ...
(Date:9/1/2017)... Ind. , Sept. 1, 2017  Explorers Like Us ... capture America,s greatest aural experiences — and deliver these experiences ... experience to help people feel and heal better. ... While nothing beats a ... and refresh your mind, Life Environments™ is the next best ...
(Date:8/29/2017)... Va. , Aug. 29, 2017 ivWatch, LLC, the ... peripheral IV infiltrations, announced it has been awarded an Innovative Technology ... company in the country. ... continuous monitoring device to aid in the early detection of peripheral ... The Innovative ...
Breaking Medicine Technology:
(Date:9/20/2017)... , ... September 20, 2017 , ... ... Maintain® methodology and industry-leading compliance software, The Guard®, has helped another long-time client ... (OCR) HIPAA audit and properly satisfy the law. , Thanks to the help ...
(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... ... digital and social campaign, “Humans With Vaginas.” The goal is to ignite conversation ... of non-toxic personal care products. The brand has declared September “Humans with Vaginas” ...
(Date:9/20/2017)... ... 20, 2017 , ... Medicare doesn’t have the authority to ... for their prescription drugs, according to a new comparison of drug plans by ... behalf, there’s no consistency in drug pricing among drug plans,” states TSCL’s Medicare ...
(Date:9/20/2017)... ... ... “The Trials I Face to Receive God’s Grace”: a mesmerizing take on ... to better one’s life through God. “The Trials I Face to Receive God’s Grace” ... places, found a love for writing. Green feels that expressing his feelings through prayer ...
(Date:9/20/2017)... ... ... Houston, Texas, investment firm CORDA Investment Management, LLC, believes in giving back. ... work and rolled up their sleeves to help with relief efforts. The team picked ... process of rebuilding. , CORDA founder Bonner C. Barnes notes that investment management firms ...
Breaking Medicine News(10 mins):